Labeling Monoclonal Antibody with α-emitting (211)At at High Activity Levels via a Tin Precursor

Background: In a previous clinical study, the authors evaluated the potential of antitenascin C monoclonal antibody (mAb) 81C6 labeled with (211)At via the prosthetic agent N-succinimidyl 3-[(211)At]astatobenzoate (SAB) for the treatment of primary brain tumors. Although encouraging results were obt...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Biother Radiopharm
Asıl Yazarlar: Vaidyanathan, Ganesan, Pozzi, Oscar R., Choi, Jaeyeon, Zhao, Xiao-Guang, Murphy, Shawn, Zalutsky, Michael R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Mary Ann Liebert, Inc., publishers 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475101/
https://ncbi.nlm.nih.gov/pubmed/32109139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2019.3204
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller